GSK Recipe For R&D: Keep Drugs In Phase II Longer, Foster Accountability

GlaxoSmithKline is holding back R&D projects in Phase II to ensure a greater chance of success later in development, R&D Chairman Tachi Yamada, MD, said during an R&D update in New York City Dec. 4